These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 21228027)

  • 1. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
    Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.
    Vermersch P; Kappos L; Gold R; Foley JF; Olsson T; Cadavid D; Bozic C; Richman S
    Neurology; 2011 May; 76(20):1697-704. PubMed ID: 21576685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
    Oliver B; Fernández O; Orpez T; Alvarenga MP; Pinto-Medel MJ; Guerrero M; León A; López-Madrona JC; Maldonado-Sánchez R; García-León JA; Luque G; Fernández V; Leyva L
    Mult Scler; 2011 Mar; 17(3):368-71. PubMed ID: 21177326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations during an elective interruption of natalizumab treatment: a post-marketing study.
    Borriello G; Prosperini L; Marinelli F; Fubelli F; Pozzilli C
    Mult Scler; 2011 Mar; 17(3):372-5. PubMed ID: 21148264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
    Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
    Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
    Warnke C; Smolianov V; Dehmel T; Andrée M; Hengel H; Zohren F; Arendt G; Wiendl H; Haas R; Hartung HP; Adams O; Kieseier BC
    Mult Scler; 2011 Feb; 17(2):151-6. PubMed ID: 21078695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deaths and disability from natalizumab are no longer tolerable: Yes.
    Duquette P
    Mult Scler; 2012 Aug; 18(8):1068-9. PubMed ID: 22807470
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Vollmer TL; Wynn DR; Alam MS; Valdes J
    Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
    Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
    Le Page E; Leray E; Edan G;
    Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
    Sørensen PS
    Mult Scler; 2012 Aug; 18(8):1070-2. PubMed ID: 22807471
    [No Abstract]   [Full Text] [Related]  

  • 18. [New drugs; natalizumab].
    van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.